Arcturus to present ARCT-810 OTC deficiency data at SSIEM 2026

Arcturus Therapeutics Holdings Inc.

Poster on ARCT-810 mRNA therapy for ornithine transcarbamylase deficiency at SSIEM 2026 in Helsinki on Aug 25, 2026
Data covers dietary intake and biochemical outcomes in adolescents and adults
Additional data and regulatory plan expected later this quarter
Presentation furnished as Exhibit 99.1 to Form 8-K

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.